Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Metal shares extended gains for a fifth consecutive trading session.
At 10:25 ST, the barometer index, the S&P BSE Sensex declined 67.43 points or 0.08% to 85,504.02. The Nifty 50 index advanced 0.10 points or 0.0% to 26,172.75.
In the broader market, the S&P BSE Mid-Cap index shed 0.01% and the S&P BSE Small-Cap index added 0.35%.
The market breadth was weak. On the BSE, 2,220 shares rose and 1,392 shares fell. A total of 237 shares were unchanged.
New Listing:
Shares of KSH International were currently trading at Rs 360.55 at 10:14 IST on the BSE, representing a discount of 6.11% as compared with the issue price of Rs 384.
The stock debuted at Rs 370 on the BSE, exhibiting a discount of 3.65% over the issue price.
So far, the stock has hit a high of 370 and a low of 355. On the BSE, over 3 lakh shares of the company were traded in the counter so far.
Buzzing Index:
The Nifty Metal index jumped 0.62% to 10,735. The index rallied 2.59% in the five consecutive trading sessions.
NMDC (up 2.47%), Hindustan Copper (up 2.43%), Welspun Corp (up 1.78%), Lloyds Metals & Energy (up 1.72%) and Hindustan Zinc (up 1.32%), National Aluminium Company (up 0.95%), Jindal Steel (up 0.76%), Jindal Stainless (up 0.73%), Steel Authority of India (up 0.6%) and Hindalco Industries (up 0.47%) surged.
Stocks in Spotlight:
Antony Waste Handling Cell surged 6.59% after the company announced that its arm, Antony Lara Enviro Solutions, has secured a contract worth Rs 329.45 crore for the development of a mixed solid waste processing plant in Maharashtra.
Glenmark Pharmaceuticals advanced 1.64%. The company said that its wholly owned subsidiary, Glenmark Pharmaceuticals Inc., USA, has announced the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial in the United States.
The company said that its Epinephrine Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) manufactured by BPI Labs, LLC (NDA 205029).
Epinephrine Injection is commonly used in emergency medical settings for the treatment of severe allergic reactions and other critical conditions.
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market recorded annual sales of approximately $67.6 million, indicating a sizeable opportunity in the US generics market.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”
Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.
Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.
Shares of Glenmark Pharmaceuticals rose 0.20% to Rs 2,042.70 on the BSE.
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2030, up 1.9% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.6% on the day, quoting at 26122.1. The Sensex is at 85390.89, up 0.54%. Glenmark Pharmaceuticals Ltd has gained around 10.18% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 1.78% in last one month and is currently quoting at 22751.25, up 0.62% on the day. The volume in the stock stood at 4.29 lakh shares today, compared to the daily average of 6.81 lakh shares in last one month.
The benchmark December futures contract for the stock is quoting at Rs 2037, up 2.12% on the day. Glenmark Pharmaceuticals Ltd is up 30.92% in last one year as compared to a 9.97% jump in NIFTY and a 1.42% jump in the Nifty Pharma index.
The PE of the stock is 38.18 based on TTM earnings ending September 25.
Glenmark Pharmaceuticals Ltd is up for a fifth straight session today. The stock is quoting at Rs 1979, up 0.2% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.14% on the day, quoting at 26010.15. The Sensex is at 85166.94, down 0.12%. Glenmark Pharmaceuticals Ltd has gained around 5.89% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 0.68% in last one month and is currently quoting at 22808.7, down 0.42% on the day. The volume in the stock stood at 1.52 lakh shares today, compared to the daily average of 11.36 lakh shares in last one month.
The benchmark December futures contract for the stock is quoting at Rs 1982.6, down 0.03% on the day. Glenmark Pharmaceuticals Ltd is up 27.57% in last one year as compared to a 5.44% jump in NIFTY and a 2.05% jump in the Nifty Pharma index.
The PE of the stock is 37.86 based on TTM earnings ending September 25.
Citing IQVIA sales data for the 12 months ending October 2025, the company said the U.S. market for Leucovorin Calcium for Injection, 350 mg/vial recorded annual sales of approximately $16.8 million, including the brand product and all available therapeutic equivalents.
Glenmark emphasized that its Leucovorin Calcium for Injection USP, 350 mg/vial is approved only for the indications listed on its FDA-approved label and is not marketed for all RLD indications.
Marc Kikuchi, President & Business Head, North America said, “We are pleased to announce the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial, further expanding our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”
The counter rose 0.24% to Rs 1,957.60 on the BSE.